Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IVA.PA
- Price
- 2.69
- Stock movement down
- -0.05 (-1.82%)
- Company name
- Inventiva S.A
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 140.85M
- Ent value
- -
- Price/Sales
- 5.44
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.27%
- 1 year return
- -14.87%
- 3 year return
- -34.08%
- 5 year return
- -7.40%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
IVA.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.44 |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 52.36M |
| EPS (TTM) | -3.07 |
| FCF per share (TTM) | -2.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 25.90M |
| Gross profit (TTM) | 24.88M |
| Operating income (TTM) | -154.96M |
| Net income (TTM) | -159.46M |
| EPS (TTM) | -3.07 |
| EPS (1y forward) | -0.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.07% |
| Operating margin (TTM) | -598.36% |
| Profit margin (TTM) | -615.73% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 0.00 |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 0.00 |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -104.23M |
| Capital expenditures (TTM) | 655.00K |
| Free cash flow (TTM) | -104.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.75 |
| Daily high | 2.75 |
| Daily low | 2.69 |
| Daily Volume | 10K |
| All-time high | 15.56 |
| 1y analyst estimate | 7.72 |
| Beta | 0.81 |
| EPS (TTM) | -3.07 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 18 Apr 2025 |
Downside potential
Loading...
Downside potential data
| IVA.PA | S&P500 | |
| Current price drop from All-time high | -82.71% | -12.89% |
| Highest price drop | -90.68% | -56.47% |
| Date of highest drop | 9 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -48.46% | -11.07% |
| Avg time to new high | 209 days | 12 days |
| Max time to new high | 1085 days | 1805 days |
COMPANY DETAILS
Marketcap
140.85M
Marketcap category
Small-cap
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Employees
123
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Here is how Elicio Therapeutics (ELTX) and Inventiva S.A. Sponsored ADR (IVA) have performed compared to their sector so far this year.
April 4, 2025
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive...
April 1, 2025
Despite a significant net loss, Inventiva SA (IVEVF) strengthens its financial position and advances its clinical trials for lanifibranor.
March 28, 2025
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gros...
March 26, 2025
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused o...
March 19, 2025
The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by improvi...
February 26, 2025
Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 tria...
February 20, 2025
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gros...
February 10, 2025
As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectr...
January 29, 2025
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
January 24, 2025
Next page